StockMarketWire.com - Circassia Pharmaceuticals reports considerable progress following the completion of recent acquisitions, with a number of important achievements across every part of the newly-enlarged business.

Circassia markets its NIOX asthma management products directly to specialists in the US and Germany, and more widely via its international network of distributors.

The company's next generation NIOX VERO product has recently been launched in a number of major markets, offering significant advantages compared with the earlier NIOX MINOc model, including improved portability, greater ease-of-use, longer life span and faster test results.

The group has issued an update for period from 1 July to 27 October which covers the first full financial quarter following the Company's acquisitions of Aerocrine AB and Prosonix Limited on 18 June and 15 June respectively.

Chief executive Steve Harris said: "Circassia has made considerable progress following the completion of our recent acquisitions, with a number of important achievements across every part of our newly-enlarged business. The phase III study of our cat allergy treatment remains on track to report in Q2 2016, and our wider allergy and respiratory franchises have made good progress with clinical studies initiated in both. Sales of our NIOX® asthma management products have grown particularly strongly during the last three months, and regulatory approval of our lead asthma product is anticipated by the end of 2015. With a strong balance sheet to deliver our pipeline we are well placed to achieve our ambition of transforming Circassia into a self-sustaining specialty biopharmaceutical company."




Story provided by StockMarketWire.com